Overview

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Status:
Suspended
Trial end date:
2024-06-20
Target enrollment:
Participant gender:
Summary
CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia and relapsed or refractory high-risk myelodysplastic syndrome.
Phase:
Phase 1
Details
Lead Sponsor:
Celgene
Celgene Corporation